5/9 2022

The magic glove

2022-05-10T12:27:41+00:00May 9th, 2022|ATI in the News|

How exactly the ReHeal Glove got to where it is now—flush with funding and undergoing various rounds of testing—is largely due to the role of the Medical Technology Enterprise Consortium (MTEC), a nonprofit corporation that operates as the premier facilitator and collaborator across the entire DOD. Indeed, if it weren’t for MTEC, the near decade-long effort to develop the ReHeal Glove may have withered on the vine. Instead, it provides a promising medical option for millions.

2/17 2022

MediWound awarded a U.S. Department of Defense research grant for the development of NexoBrid for the U.S. Army

2022-02-24T15:28:09+00:00February 17th, 2022|ATI in the News|

MediWound Ltd., a fully-integrated biopharmaceutical company focused on next-generation bio therapeutic solutions for tissue repair and regeneration, today announced that the U.S. Department of Defense (DoD), through the Medical Technology Enterprise Consortium (MTEC), has awarded MediWound a $1.7 million research project for the development of NexoBrid® as a non-surgical solution for field-care burn treatment for the U.S. Army (the "MTEC Research Project Award").

11/17 2021

Double time

2021-11-22T13:46:10+00:00November 17th, 2021|ATI in the News|

“We need to place cutting-edge technology quickly into the hands of the warfighter,” said Sara Langdon, USAMRDC’s program manager for other-transaction authority with the Medical Technology Enterprise Consortium (MTEC). “It is vital that we partner in order to fill our medical capability gaps, and OTAs help us to accomplish this.”

11/10 2021

Imbed Biosciences wins a $2M award from the U.S. Army to prevent combat wound infections

2021-11-11T16:28:05+00:00November 10th, 2021|ATI in the News|

Imbed Biosciences, Inc. (Imbed) announced today that it has been awarded a contract for $1,999,481 by the U.S. Army Medical Research and Development Command's (USAMRDC) Military Infectious Diseases Research Program (MIDRP) to accelerate clinical development of an antibiofilm version of its next-generation Microlyte® Matrix wound dressing that can kill bacteria hidden in biofilms. The contract was awarded through Medical Technology Enterprise Consortium (MTEC) for prototype solutions that prevent combat wound infections following blast injuries and burns.

10/26 2021

DOD funds $4.3M human trial on device to enhance sleep

2021-11-01T11:50:12+00:00October 26th, 2021|ATI in the News|

This project, titled “Augmented Neurophysiology of Sleep and Performance Readiness,” is part of the Medical Technology Enterprise Consortium, a collaboration between industry and academia to facilitate research and development activities, in cooperation with the U.S. Army Medical Research and Development Command and other Department of Defense agencies in the biomedical sciences to protect, treat, and optimize the health and performance of military personnel.

10/6 2021

Lumen Bioscience awarded federal funding to advance Covid-19 antibody cocktail through Phase 2 Clinical Evaluation

2021-10-06T19:54:41+00:00October 6th, 2021|ATI in the News|

Lumen Bioscience—a clinical-stage biopharmaceutical company developing biologic drugs for highly prevalent diseases—today announced new development funding from the US Army for its Covid-19 monoclonal antibody drug cocktail. The support is provided by the US Army Medical Research and Development Command (USAMRDC), operating through the Medical Technology Enterprise Consortium (MTEC).

10/1 2021

UAB to study hand-held device that monitors traumatic brain injury

2021-10-04T20:06:31+00:00October 1st, 2021|ATI in the News|

Researchers at the University of Alabama at Birmingham will investigate the usefulness of a new non-invasive method to measure the expansion of hematomas in the brain. This project is funded by the Combat Casualty Care Research Program’s Neurotrauma Program at the US Army Medical Research and Development Command via the Medical Technology Enterprise Consortium.

Go to Top